Barrett’s Oesophagus
Barrett’s oesophagus is not cancer.
Barrett’s without dysplasia
The chance of developing oesophageal cancer is low. Most people with Barrett’s never develop it, and the risk is lower still when the segment is short.
Surveillance gastroscopies are measured in years, not months. You do not need to live as though you have cancer, restrict your diet, or worry about your oesophagus between appointments.
If your report mentions dysplasia
Dysplasia is still not cancer, but some Barrett’s cells have developed important precancerous changes. It needs timely specialist follow-up rather than waiting for a routine gastroscopy.
Dysplasia — and many very early cancers — can now usually be treated through the gastroscope, without major surgery.
What is Barrett’s?
The oesophagus, or gullet, carries food from your mouth to your stomach. Small amounts of reflux happen normally in everyone; gastro-oesophageal reflux disease (GORD) means reflux that causes troublesome symptoms or damage.
After years of reflux, the lining of the lower oesophagus can change. I think of the normal microscopic lining as “white tiles”. In Barrett’s, some are replaced by more gland-like “red bricks” that produce protective mucus and cope better with stomach contents.
Barrett’s is found in roughly 1–2 people in every 100, and in around 5–10% of people with GORD. Many have little or no heartburn and only discover it during a gastroscopy done for another reason.
Most people with occasional reflux do not need a gastroscopy just to look for Barrett’s. It becomes more reasonable with longstanding reflux plus other risk factors — increasing age, male sex, obesity, smoking, or a close family history of Barrett’s-related oesophageal cancer.
How is Barrett’s diagnosed?
Barrett’s is diagnosed at gastroscopy. The gastroenterologist identifies where the stomach ends and the oesophagus begins, measures any Barrett’s segment, and takes small biopsies.
The junction between oesophagus and stomach is called the Z-line, and small irregularities here are common. If the lining extends less than 1 cm above the stomach — an irregular Z-line — this is generally not classified as Barrett’s and does not need surveillance, even if a tiny focus of intestinal metaplasia is found by chance.
1Normal junction
The Z-line and the gastro-oesophageal junction (GOJ) are at the same level (0 cm). This is normal.
2Irregular Z-line
Small tongues of stomach-type lining rise less than 1 cm above the GOJ. This is not Barrett’s oesophagus.
3Short segment
Barrett’s oesophagus present. Circumferential extent (C) is 1 cm. Maximum extent (M) is 2 cm.
Prague C1 M2
4Long segment
Barrett’s oesophagus present. Circumferential extent (C) is 6 cm. Maximum extent (M) is 8 cm.
Prague C6 M8
- Pale oesophageal liningsquamous
- Salmon stomach-type liningcolumnar
- Z-linesquamo-columnar junction
- GOJgastro-oesophageal junction
- Ccircumferential extent
- Mmaximum extent
What does my biopsy result mean?
Barrett’s without dysplasia
The usual and most reassuring result. Barrett’s cells are present, but no dysplasia has been found. The next gastroscopy will usually be years away.
Indefinite for dysplasia
Inflammation can make cells look abnormal without the pathologist being able to diagnose dysplasia confidently. This is an uncertain result rather than a risk category, and needs expert review, control of inflammation and another carefully timed gastroscopy.
Low-grade dysplasia
Low-grade dysplasia means the biopsy appears to show early precancerous changes — but low-grade dysplasia is genuinely difficult to diagnose. When slides are reviewed by an expert gastrointestinal pathologist, about 3 in 4 initial diagnoses are changed to no dysplasia or an uncertain result.
Low-grade dysplasia should always be confirmed by expert pathology before any decision is made.
High-grade dysplasia
A more advanced precancerous change, needing prompt specialist assessment and usually treatment rather than watching.
Barrett’s cancer risk
For Barrett’s without dysplasia, the risk is low and depends partly on segment length. In pooled studies, the annual risk of oesophageal adenocarcinoma was about:
Barrett’s under 3 cm
0.06%
per year — about 1 in 1,700 each year
Barrett’s 3 cm or longer
0.31%
per year — about 1 in 320 each year
These are annual population averages, not predictions about you. Most people with Barrett’s without dysplasia never develop oesophageal cancer. Over many years the cumulative chance does rise, and risk is somewhat higher with increasing age, male sex, smoking and a family history of Barrett’s-related oesophageal cancer.
Once dysplasia appears, the picture changes
The first year after low-grade dysplasia is diagnosed deserves particular attention. In carefully reviewed cohorts, around 9 in 100 patients had high-grade dysplasia or cancer identified during that first year. Much of this probably represents more advanced disease that was already present but not recognised initially, which is why expert pathology review and an early careful gastroscopy matter.
Once that initial assessment has excluded more advanced disease, subsequent risk is considerably lower. Across broader studies, progression to high-grade dysplasia or cancer averages around 1–2% per year, although the risk varies considerably according to how confidently low-grade dysplasia is diagnosed and what happens on subsequent biopsies.
Someone who has remained stable through years of careful surveillance is therefore in a different situation from someone newly diagnosed. Persistent dysplasia still deserves surveillance, but the initial concern about an already-present, missed cancer has largely been resolved.
With confirmed high-grade dysplasia, the risk of cancer is substantial — of the order of several per cent each year — which is why treatment is usually recommended rather than routine surveillance.
How often do I need a surveillance gastroscopy?
For Barrett’s without dysplasia, surveillance is deliberately infrequent. The purpose is not to keep proving Barrett’s is still there — it is to find the uncommon person who develops dysplasia or a very early cancer, while treatment is straightforward.
A useful contemporary guide is:
- No surveillance Irregular Z-line under 1 cm, even if a tiny focus of intestinal metaplasia is found
- Around 5 years Barrett’s 1 to less than 3 cm
- Around 3 years Barrett’s 3 cm or longer
Guidelines vary on these intervals, and surveillance is individualised — your gastroenterologist may adjust it according to your biopsies, age, general health, smoking and family history.
A short segment that looks like Barrett’s but shows no intestinal metaplasia on good-quality repeat biopsies can usually leave surveillance altogether.
If dysplasia is confirmed, follow-up becomes more frequent and is tailored to whether you are having surveillance or endoscopic treatment. Surveillance continues after successful treatment because Barrett’s or dysplasia can recur.
Between gastroscopies
See your doctor if you develop a new symptom lasting more than two weeks, recurring, or worsening:
- difficulty or pain on swallowing
- unexplained weight loss
- persistent vomiting
- unexplained iron-deficiency anaemia
Seek prompt attention rather than waiting if food is sticking, you vomit blood, or you have black bowel motions.
Most changes in reflux symptoms do not mean cancer, but new persistent or worsening symptoms deserve assessment.
If dysplasia is found
Low-grade dysplasia: surveillance or ablation?
This is the one situation where you face a genuine choice, so it is worth understanding.
The first step is certainty about the diagnosis. Biopsies should be reviewed by an expert gastrointestinal pathologist, and a careful repeat gastroscopy may be needed to look for a subtle visible abnormality, which can then be removed through the gastroscope and examined properly.
If low-grade dysplasia is confirmed, radiofrequency ablation (RFA) reduces the risk of progressing to high-grade dysplasia or cancer. Close surveillance remains a reasonable alternative for some people, particularly if low-grade dysplasia is not repeatedly confirmed, or if avoiding treatment is an important preference.
RFA usually needs more than one gastroscopy and can cause temporary chest discomfort. A small number of people develop narrowing of the oesophagus requiring stretching; serious bleeding or perforation are uncommon.
Surveillance avoids treatment that may never have been necessary, but means accepting a higher risk of progression and more frequent gastroscopies.
An Australian practical point Medicare currently funds RFA for Barrett’s with confirmed high-grade dysplasia, but not for low-grade dysplasia. Choosing RFA for low-grade dysplasia may therefore involve significant out-of-pocket costs, and this is worth discussing openly before you decide.
The right choice depends on how confidently the dysplasia has been confirmed, whether it persists, the length of your Barrett’s segment, your general health, cost and your own preference.
High-grade dysplasia
High-grade dysplasia needs prompt specialist assessment, and is usually treated rather than kept under routine surveillance.
Visible abnormalities are removed endoscopically, and the remaining Barrett’s lining can then be eradicated, commonly with ablation. For suitable early disease, modern treatment often avoids oesophagectomy.
Barrett’s without dysplasia does not need eradication treatment.
Anti-reflux surgery may help selected people with troublesome reflux, but it is not used as cancer-prevention treatment for Barrett’s.
Do I need acid-reducing medication?
Proton pump inhibitors (PPIs) are very effective for reflux and for healing inflammation of the oesophagus. If you have troublesome reflux or oesophagitis, there is a clear reason to take one.
Whether a PPI also prevents cancer is less certain. Some studies suggest PPIs may reduce progression of Barrett’s, and several guidelines recommend a daily PPI for this reason.
The largest randomised trial found some benefit from high-dose compared with standard-dose PPI when death, high-grade dysplasia and cancer were considered together, but it did not show fewer oesophageal cancers. No randomised trial has compared PPI treatment with no PPI treatment.
The dose is usually guided by control of reflux and healing of oesophagitis rather than assuming that more acid suppression gives more cancer protection.
What should I eat?
There is no special Barrett’s diet.
Eat a generally healthy diet, maintain a healthy weight, and avoid smoking. Avoid particular foods only if they actually trigger reflux for you — there is no reason to ban coffee, tomatoes, curry, chocolate or spicy food because of Barrett’s.
If fear of Barrett’s has caused you to restrict food or lose weight, please speak with your doctor.
If you have Barrett’s without dysplasia, the odds are overwhelmingly in your favour.
If you have dysplasia, don’t panic — but make sure you have a clear specialist follow-up plan.
Barrett’s deserves appropriate follow-up, not fear.
This information is general and does not replace advice from your own doctor. Your surveillance and treatment plan should be based on your individual endoscopy findings, biopsy results and overall health.
Reviewed and updated August 2026.